Effect of S100A8 and S100A9 on expressions of cytokine and skin barrier protein in human keratinocytes

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease. Clinical observations used to diagnose AD include chronic dermatitis, pruritus, facial and extensor eczema in infants and children and flexural eczema in adults (1–3). The prevalence of AD is increasing annually.

S100A8 and S100A9 are members of the S100 family proteins, having constitutive or inducible expressions in neutrophils and monocytes/macrophages (4). These proteins are included in damage-associated molecular pattern (DAMP), and perform various functions, including control of cell motility, protein phosphorylation for cell activation, and calcium homeostasis for tumor progression or suppression through Toll-like receptor 4 (TLR4) (4,5). High levels of S100 calcium binding protein A8 (S100A8) and S100A9 are characteristic of several inflammatory conditions, such as chronic inflammatory bowel disease, rheumatoid arthritis, cystic fibrosis, psoriasis and AD (6,7).

Cytokine dysregulation is one of the most important pathogenic mechanisms associated with AD. Interleukin-6 (IL-6), IL-8, and monocyte chemoattractant protein-1 (MCP-1) are essential cytokines involved in the induction and alleviation of AD (8). In addition, defects in skin barrier function are critical for the development of AD (9). Disruption of skin barrier proteins, including filaggrin, loricrin and involucrin, can make it easier for allergens or antigens to permeate the skin (9). Such defects may be the result of an increase in cytokines or may result in increased production of inflammatory cytokines, including IL-1, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor-α (TNF-α), and MCP-1. These cytokines and chemokines may both induce and alleviate AD (8,9).

Based on the above, this study was performed to investigate whether S100A8 and S100A9 are associated with alteration of cytokine secretion and skin barrier proteins.

Materials and methods

Reagents

TLR4 inhibitor CLI-095 (TLR4i), protein kinase δ (PKCδ) inhibitor (rottlerin), p38 mitogen-activated protein kinase (MAPK) inhibitor (SB202190), MEK inhibitor (PD98059) and nuclear factor-κB (NF-κB) inhibitor (BAY-11-7085) were obtained from Calbiochem (Merck KGaA). Antibodies against p38 MAPK (cat. no. 9212), phospho-p38 MAPK (cat. no. 9211), phospho-extracellular signal regulated kinase 1/2 (ERK1/2; cat. no. 9101), rabbit IgG-HRP (cat. no. 7074), and mouse IgG-HRP (cat. no. 7076) were acquired from Cell Signaling Technology, Inc. Anti-ERK2 (cat. no. sc-154) and anti-TLR4 (cat. no. sc-10741) antibodies were obtained from Santa Cruz Biotechnology, Inc.

Production of recombinant S100A8 and S100A9 proteins

In our previous report, the cDNA of human S100A8 and S100A9 was cloned into pET28 expression vector (Merck KGaA) (10). Recombinant S100A8 and S100A9 expression was induced with 1 mM isopropyl β-D-thiogalactoside in E. coli BL21 (DE3; Merck KGaA). Subsequently, bacteria were centrifuged at 5,000 × g for 10 min at 4°C and the pellet was lysed in BugBuster Protein Extraction reagent (Merck KGaA). A spectrophotometer (Thermo Fisher Scientific, Inc.) was used for measuring protein concentration in the lysates.

Cell culture

Human keratinocytic HaCaT cells (Addexbio; cat. no. T0020001) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (cat. no. 12484-010; Gibco; Thermo Fisher Scientific, Inc.), penicillin (100 U/ml), and streptomycin (100 µg/ml). The cultured cells were maintained at sub-confluency in a 95% air, 5% CO2 humidified atmosphere at 37°C. An Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (BD Biosciences) and an RF500 flow cytometer (Sysmex Corporation) were used to evaluate the cytotoxicity.

ELISA

HaCaT cells were treated with S100A8 or S100A9 for 6, 12, 24 and 48 h, followed by centrifugation of the supernatant at 5,000 × g for 10 min at 4°C. The concentrations of IL-6, IL-8 and MCP-1 in the cell supernatant were measured with a sandwich ELISA using OptEIA™ Set human IL-6 (cat. no. 555220), IL-8 (cat. no. 555244) and MCP-1 (cat. no. 555179; all BD Biosciences) according to the manufacturer's protocol.

Western blotting

HaCaT cells were treated with S100A8 or S100A9 for 24 h, and the cells were harvested and lysed with lysis buffer (TransLab). The homogenate was centrifuged at 12,000 × g for 15 min at 4°C, and the supernatant was collected as total lysate. Protein concentration of the lysate was measured by a protein assay kit (Thermo Scientific, Inc.). Following separation of the protein samples (50 mg/lane) by 10% SDS-PAGE, the transferred nitrocellulose membranes were incubated with primary (1:1,000) and secondary antibodies as described in the reagents section (1:3,000) for 1 h at room temperature, and developed by using an enhanced chemiluminescence detection system (Amersham; GE Healthcare, Chicago, IL, USA). The same blot was stripped and re-probed with anti-ERK2 or anti-β-actin antibodies as described in the reagents section used as an internal control.

NF-κB p65 transcription factor assay

The DNA-binding activity of NF-κB was assessed by using EZ-Detect™ transcription factor kits for NF-κB p65 (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. DNA-binding specificity was evaluated by using wild type (5′-CACAGTTGAGGGGACTTTCCCAGGC-3′) or mutant NF-κB oligonucleotides (5′-CACAGTTGAGGCCACTTTCCCAGGC-3′). Chemiluminescent detection was performed using a luminometer (Thermo Fisher Scientific, Inc.).

Statistical analysis

All data (n=38) are presented as the mean ± standard deviation. Data were analyzed by using a paired Student's t-test for two-group comparisons and a one-way analysis of variance with Tukey's post hoc tests for comparisons of more than two groups. Analyses were performed using the SPSS statistical software package, version 10.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

S100A8 and S100A9 induce expression of IL-6, IL-8, and MCP-1 in HaCaT cells, which is associated with TLR4, PKCδ, ERK, p38 MAPK and NF-κB signaling pathways

The protein expression levels of IL-6, IL-8 and MCP-1 were significantly increased in a time and dose-dependent manner following S100A8 or S100A9 treatment, in HaCaT cells (Figs. 1 and 2). To evaluate the signaling mechanism(s) induced by S100A8 and S100A9 treatment, alteration of the cytokine expression was evaluated by pretreatment with protein-specific inhibitors prior to S100A8 and S100A9 stimulation. As demonstrated in Fig. 3, the expression levels of IL-6, IL-8, and MCP-1 increased by S100A8 or S100A9 treatment, were significantly reduced by specific inhibitors, including TLR4i, rottlerin, PD98059, SB203580 and BAY-11-7085. These results confirmed that TLR4, PKCδ, ERK, p38 MAPK and NF-κB signaling pathways are involved in S100A8 or S100A9-induced secretion of IL-6, IL-8 and MCP-1.

Figure 1. HaCaT cells treated without (Con) or with 10 µg/ml of (A) S100A8 or (B) S100A9 had increased IL-6, IL-8, and MCP-1 production levels in a time-dependent manner, as measured by ELISA. Data are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. Con. S100, calcium binding protein; Con, control; IL, interleukin; MCP, monocyte chemoattractant protein.

Figure 2. HaCaT cells were treated with the indicated concentrations (µg/ml) of (A) S100A8 or (B) S100A9 for 48 h and IL-6, IL-8, and MCP-1 were released in a dose-dependent manner, as measured by ELISA. Data are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. the control. S100, calcium binding protein; IL, interleukin; MCP, monocyte chemoattractant protein.

Figure 3. HaCaT cells were pretreated for 1 h with and without 5 µM TLR4i, 5 µM Rt, 10 µM PD, 10 µM SB or 2 µM BAY, followed by incubation with (A) S100A8 or (B) S100A9 for 48 h. Data are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. the control. IL, interleukin; S100, calcium binding protein; TLR, toll-like receptor; TLR4i, CLI-095; Rt, rottlerin; PD, PD98059; SB, p38 mitogen-activated protein kinase inhibitor; BAY, BAY-11-7085; MCP, monocyte chemoattractant protein.

S100A8 and S100A9 induce activation of ERK, p38 MAPK and NF-κB signaling pathways

Since the signaling inhibitors blocked cytokine release induced by S100A8 and S100A9, whether S100A8 and S100A9 induce activation of MAPK and NF-κB signaling pathways was examined. Following stimulation with S100A8 and S100A9, phosphorylation of ERK and p38 MAPK was induced, reaching maximal phosphorylation levels at 1 h (Fig. 4A). Additionally, ERK and p38 MAPK activation induced by S100A8 and S100A9 was blocked by TLR4i and rottlerin (Fig. 4B). These results indicated that S100A8 and S100A9 activate ERK and p38 MAPK signaling pathways via TLR4 and rottlerin. As shown in Fig. 5, both S100A8 and S100A9 NF-κB activity in a time-dependent manner, and this activation was suppressed by TLR4i, rottlerin, PD98059 and SB202190. In addition, TLR4 expression was upregulated by S100A8 and S100A9 (Fig. 6). These results indicated that S100A8 and S100A9 may activate NF-κB via TLR4, PKCδ, ERK and p38 MAPK signaling pathways.

Figure 4. S100A8 and S100A9 induced activation of ERK and p38 MAPK. (A) HaCaT cells were incubated with S100A8 and S100A9 (10 µg/ml) for the indicated times and phosphorylation of ERK and p38 MAPK in the lysates was measured by western blotting. (B) HaCaT cells were pretreated for 1 h with and with 5 µM TLR4i or 5 µM Rt, followed by incubation with S100A8 and S100A9 (10 µg/ml) and p-ERK and p-p38 MAPK in the lysates were measured by western blotting. Data are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 S100A8/A9-treated group vs. the control and inhibitor-treated group vs. S100A8/A9-treated group. S100, calcium binding protein; p-, phosphor-; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; TLR, toll-like receptor; TLR4i, CLI-095; Rt, rottlerin.

Figure 5. S100A8 and S100A9 induced NF-κB activation. (A) HaCaT cells were incubated with S100A8 and S100A9 (10 µg/ml) for the indicated times. (B) HaCaT cells were pretreated for 1 h with and with 5 µM TLR4i, 5 µM Rt, 10 µM PD or 10 µM SB, followed by incubation with S100A8 or S100A9 (10 µg/ml) for 1 h and NF-κB in the lysates was measured by luciferase activity assay. Data are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 S100A8/A9-treated group vs. the control and inhibitor-treated group vs. S100A8/A9-treated group. NF-κB, nuclear factor-κB; S100, calcium binding protein; TLR, toll-like receptor; TLR4i, CLI-095; Rt, rottlerin; PD, PD98059; SB, p38 mitogen-activated protein kinase inhibitor.

Figure 6. HaCaT cells were treated with (A) S100A8 or (B) S100A9 (10 µg/ml) for 24 h and TLR4 expression was increased as assessed by western blotting. Data are expressed as the mean ± standard deviation. **P<0.01 vs. the control. S100, calcium binding protein; TLR4, toll-like receptor 4.

Filaggrin and loricrin expression levels are decreased by S100A8 and S100A9

As skin barrier proteins are important in the pathogenesis of AD, whether S100A8 and S100A9 alter the expression of filaggrin, loricrin and involucrin was examined. The expression levels of filaggrin and loricrin were decreased following stimulation with S100A8 or S100A9; whereas involucrin expression was not altered (Fig. 7). These results indicated that S100A8 and S100A9, in addition to regulating cytokine production, may also regulate skin barrier proteins expression.

Figure 7. HaCaT cells were treated with (A) S100A8 or (B) S100A9 (10 µg/ml) for 24 h and filaggrin and loricrin expression levels were decreased as assessed by western blotting. Data are expressed as the mean ± standard deviation. **P<0.01 vs. the control. S100, calcium binding protein.

Discussion

The S100 proteins have calcium-binding capacity and can induce a variety of inflammatory responses. S100A8 and S100A9 are produced by neutrophils, monocytes, macrophages, and keratinocytes and their expression levels are increased under inflammatory conditions (4). IL-1α is produced by epithelial cells and acts autonomously on those cells to induce the expression of S100A9 and cellular differentiation (11). Decreased hydration induces the expression of S100A8 and S100A9, resulting in an increase in hypertrophic scarring (12). In addition, S100A8 and S100A9 levels are increased in lesional skin of patients with AD (13,14). In the present study, it was examined whether S100A8 and S100A9, which are involved in AD, alter the expression levels of cytokines and skin barrier proteins. S100A8 and S100A9 increased the expression of IL-6, IL-8, and MCP-1 in human keratinocytes. MCP-1 is a member of the C-C chemokine family and a potent chemotactic factor in monocytes that can modulate the migration and invasion of macrophages, memory T cells and natural killer cells (8). Additionally, MCP-1 is implicated in a variety of inflammatory diseases, including asthma, rheumatoid arthritis and chronic idiopathic urticarial (8). Furthermore, increased expression of MCP-1 contributes to the proinflammatory environment in AD (8,15). IL-6 serves essential roles in the transition from acute to chronic inflammation. IL-8 secreted by macrophages is associated with inflammatory conditions. The complex interaction of these cytokines with chemokines may evoke AD pathogenesis (15). In addition, immunological reactions induced by S100 proteins include intracellular and extracellular signaling. The human keratinocytic HaCaT cell has low basal endogenous and exogeneous expression of S100A8 and S100A9 (16). Although it is expected that inflammatory cytokines induce intracellular expression or secretion of S100A8 and S100A9, the exact stimuli are still unknown and needs to be investigated further.

Defects in skin barrier function are an essential feature of the development of AD (17). Although filaggrin, loricrin, and involucrin are three key proteins in skin barrier functions, S100A8 and S100A9 treatment was effective only on the expressions of filaggrin and loricrin with no effect on involucrin expression. These results indicated that S100A8 and S100A9 may have specific inhibitory effects on skin barrier proteins. IL-6 is negatively associated with filaggrin expression, and decreased expression of filaggrin elicits expression of IL-8 and MCP-1 (18,19). Since skin barrier proteins are associated with cytokine secretion, there may be several mechanisms involved in the increase of cytokine secretion and the decrease of filaggrin and loricrin expressions induced by S100A8 and S100A9. Further studies are required to investigate the S100A8- and S100A9-associated mechanisms affecting the expression and function of skin barrier proteins, such as filaggrin and loricrin, and cytokine release.

MAPK is a typical signaling transduction pathway that transduces extracellular stimulation from the cell membrane to the intracellular nucleus (20). MAPK, which is activated by receptors that bind with growth hormones, cytokines and stressors, is involved in a variety of cellular functions, including cell proliferation, differentiation, and apoptosis (21). In the current study, S100A8 and S100A9 induced activation of ERK and p38 MAPK. Both ERK (ERK1/2) and p38 MAPK have important roles in cytokine secretion and allergic diseases, including AD (21,22). c-Jun N-terminal kinase (JNK) is an important MAPK associated with filaggrin expression (17). Further studies are required to investigate the association between the alteration of skin barrier proteins and JNK activation. In addition, the present results demonstrated that TLR4 is elevated following S100A8 and S100A9 treatment. It can be hypothesized that the increased TLR4 expression levels due to S100A8 and S100A9 treatment enhance cytokine secretion induced by S100A8 and S100A9 via TLR4; this positive feedback loop may result in alleviation of AD.

In summary, S100A8 and S100A9 promote cytokine production, which is critical in the inflammation response, and decrease filaggrin and loricrin expression levels. These observations indicate that S100A8 and S100A9 may be important molecules in the pathogenesis and progression of AD.

Acknowledgements

Not applicable

Funding

This study was supported by the BK21 plus program through the National Research Foundation (NRF) funded by the Ministry of Education of Korea and by Sysmex Korea Inc. (grant no. 19-001).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MJK wrote manuscript, performed the experiments, and analyzed the data. MAI and JSL performed the experiments and analyzed the data. JYM, DHK, and AG interpreted the data. ISK conceived the study, designed the experiments, and reviewed the paper.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References